Thursday's Analysts' Upgrades and Downgrades

CHANGE IN RATINGS

Accenture (ACN Quote) downgraded at Morgan Stanley from overweight to equalweight and lowers price target from $48 to $42.

Akamai (AKAM Quote) downgraded at Kaufman to Sell from Hold. Cites intensifying competition among existing players and new entrants will pressure earnings. Reduced target price to $25 from $33.

AMR (AMR Quote) downgraded at Goldman Sachs to Sell from Neutral based on expected weak performance in PRASM (relative to peers) along with continuing domestic pressures. Atlantic traffic is weighted to UK, leaving company vulnerable to deteriorating economic outlook. Price target cut to $22 from $25.

Biocryst (BCRX Quote) downgraded at ThinkEquity to an Accumulate rating following announcement of disappointing Peramivir data. Target cut to $10. ...